Matthew J. Niederst

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

Aaron N. Hata, Matthew J. Niederst, Hannah L. Archibald et al. · Nature Medicine · 2016 · 999 citations · Full text

Medicine, Cancer Biology, Oncology +15

Patient-derived models of acquired resistance can identify effective drug combinations for cancer

Adam Crystal, Alice T. Shaw, Lecia V. Sequist et al. · Science · 2014 · 733 citations

Medicine, Oncology, Pharmacology +17

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

Matthew J. Niederst, Lecia V. Sequist, John T. Poirier et al. · Nature Communications · 2015 · 633 citations · Full text

Medicine, Cancer Biology, Oncology +17

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

Matthew J. Niederst, Haichuan Hu, Hillary E. Mulvey et al. · Clinical Cancer Research · 2015 · 548 citations · Full text

Medicine, Oncology, Pharmacology +14

Heterogeneity Underlies the Emergence of <i>EGFR</i> T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor

Zofia Piotrowska, Matthew J. Niederst, Chris Karlovich et al. · Cancer Discovery · 2015 · 460 citations · Full text

Medicine, Oncology, Pharmacology +16